Patrick Campbell

This American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.

Ahmad Masri, MD, MS, provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond cardiomyopathy.

Tom Nguyen, MD, discusses a recent study he led comparing outcomes of TAVR explantation based on transcatheter heart valve type.

FDA advisory committee votes 13-1 that the benefits outweigh the risk of use for Abbott's TriClip for tricuspid regurgitation, pending FDA decision expected in 2024.

Michelle Kittleson, MD, PhD, provides insight into the potential impact of a new risk score for heart transplant allocation as well as the need for more equitable cardiovascular care in the US.

A novel risk score developed by University of Chicago investigators outperformed conventional models in predicting death in heart transplant candidates, which could help bring the field closer to optimal and equitable allocation.

A trial comparing iron supplementation methods for postpartum maternal fatigue found similar fatigue reduction regardless of treatment type.

A recent survey indicates many US adults are unaware of their vital health metrics, highlighting the need for increased education on heart disease prevention.

Deepak Bhatt, MD, MPH, discusses the need to improve in-hospital initiation and uptitration of guideline-directed medical therapy in heart failure.

According to a new systematic review and meta-analysis, roxadustat's efficacy remains consistent across varying inflammation levels in patients with chronic kidney disease.

This recap of top cardiology news from January 2024 spotlights pipeline updates, new guidance on peripheral interventions, and a celebration of what may be the single most impactful public health address in the history of the United States.

The FDA's acceptance of the NDA for acoramidis in ATTR-CM was announced on February 05, 2024 and assigns a November 2024 PDUFA for the agent.

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

In the wake of Vera Therapeutics announcing positive 72-week data from the phase 2b ORIGIN trial, we sat down with lead investigator Richard Lafayette, MD, to learn more about how he interprets the latest data from the atacicept program in IgA nephropathy.

This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue

In this feature, we acknowledge the impact of the 1964 Surgeon General report, its subsequent effect on public health, and present-day hurdles to optimized public health efforts through the eyes of our editorial advisory board members and other leading experts.

In an interview, Andrew Blauvelt, MD, MBA, provides further perspective on the approval of roflumilast topical foam, 0.3% (Zoryve) and full publication of phase 3 STRATUM data.

Study with 150,000 adults reveals 10% or more of unintentional weight loss associated with an elevated rate of cancer diagnosis within the next 12 months.

This cardiology case report from Brady Pregerson, MD, features a woman in her 50s presenting with 3 days of body swelling and dyspnea. Check out the EKG and see if you can determine the correct diagnosis!

A systematic review of over 400 studies in type 2 diabetes reveals 13 biomarkers, including NT-proBNP and troponin-t, with potential to significantly enhance cardiovascular disease risk prediction.

The 72-week open-label extension of the phase 2b ORIGIN trial reveals atacicept's potential as a disease-modifying treatment for IgA nephropathy, showing eGFR stabilization and improvements in key indicators

On January 25, 2024, the day following the proposed PDUFA goal date, Liquidia Corporation announced the FDA was still reviewing the NDA for pulmonary hypertension with interstitial lung disease for treprostinil inhalation powder (Yutrepia).

The American Heart Association's annual report on heart disease and stroke statistics for 2024 sheds new light on the impact and level of public education surrounding the impact of heart disease and stroke in the US and abroad.

A study of EHR workload trends reveals a concerning increase in primary care providers' time spent in the EHR post-pandemic, with providers spending 28 more minutes each workday on EHR-related tasks now relative to 2019.

Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.

In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.

Analysis finds measures of iron deficiency, including ferritin, serum iron, and transferrin, were linked to an increased likelihood of depression in young adult males but not females.

Results of the PRECISION trial suggest use of iron-whey-protein microspheres could aid in improving adherence to oral iron therapy as well as staving off adverse GI events.